Supplementary Table S3. Delivered care for heart failure patients in participating centers according to heart failure subspecialized care.
| HF Subspecialized Care | |||
|---|---|---|---|
| Not Available (n=48) | Available (n=42) | p-value | |
| BNP dosage | 65% (31/48) | 58% (33/57) | ns |
| Centers with BNP | |||
| Help in the diagnosis | 71% (22/31) | 73% (24/33) | ns |
| Determine the prognosis | 65% (20/31) | 58% (19/33) | ns |
| Help the treatment | 42% (13/31) | 24% (8/33) | ns |
| Monitoring | 62% (19/31) | 55% (18/33) | ns |
| Centers with no BNP | |||
| Lack of access | 100% (7/7) | 75% (6/8) | ns |
| Considered not essential | 0% (0/6) | 38% (3/8) | ns |
| Education program for patient | 53% (18/34) | 41% (16/39) | ns |
| Education program for caregivers | 17% (6/35) | 31% (12/39) | ns |
| Written instructions at hospital discharge | 77% (27/35) | 90% (36/40) | ns |
| By Doctor | 79% (19/24) | 56% (19/34) | ns |
| By Nurse | 21% (5/24) | 41% (14/34) | |
| By Others | 0% (0/24) | 2.9% (1/34) | |
| Patient monitoring programs | 23% (7/31) | 51% (20/39) | 0.014 |
| Using monitoring program | |||
| At ambulatory using non-doctorspecialized monitoring | 3.2% (1/31) | 33% (13/39) | 0.002 |
| At distance using phone or other methods | 10% (3/31) | 18% (7/39) | ns |
| Regular use of HF guidelines | 84% (27/32) | 95% (38/40) | ns |
| DEIC | 52% (14/27) | 45% (17/38) | ns |
| ESC | 26% (7/27) | 21% (8/38) | |
| AHA | 19% (5/27) | 18% (7/38) | |
| Institution's own protocol | 3.7% (1/27) | 13% (5/38) | |
| Other guidelines | 0% (0/27) out of 27) | 2.6% (1/38) | |
| Not following guidelines | 19% (5/27) | 5.3% (2/38) | |
| Using quality of life questionnaire | 23% (7/31) | 29% (11/38) | ns |
| KCCQ | 6.5% (2/31) | 5.3% (2/38) | ns |
| MLHFQ | 16% (5/31) | 24% (9/38) | ns |
| Other | 3.2% (1/31) | 2.6% (1/38) | ns |
| Cardiac rehabilitation | 27% (8/30) | 76% (29/38) | <0.001 |
| Key performance indicators | 50% (14/28) | 56% (20/36) | ns |
| Hospital mortality | 25% (7/28) | 36% (13/36) | ns |
| 6-month mortality | 18% (5/28) | 22% (8/36) | ns |
| 30-day hospitalization after discharge | 25% (7/28) | 39% (14/36) | ns |
| 90-day hospitalization after discharge | 4% (1/28) | 22% (8/36) | 0.066 |
| Hospitalization duration | 18% (5/28) | 30% (11/36) (11 out of 36) | ns |
| Other | 0% (0/28) | 6% (2/36) | ns |
| Medical decision in hospitalized patient in decompensated HF | |||
| By hospital cardiology team | 41% | 45% | <0.001 |
| By cardiologist who cares for the patient in the outpatient clinic | 45% | 42% | <0.001 |
| By intensive care unit doctors if admitted in intensive care unit | 14% | 12% | 0.067 |
| Beginning of HF treatment | |||
| Cardiologist in hospital | 41% | 45% | <0.001 |
| Cardiologist in ambulatory | 41% | 31% | <0.001 |
| General practitioner | 6% | 14% | <0.001 |
| Intensive care doctor | 9% | 3% | <0.001 |
| Geriatrics | 1% | 2% | ns |
| Others | 2% | 4% | ns |
| Prescribed HF treatment | |||
| ACE-I | 97% (33/34) | 95% (38/40) | ns |
| ARBs | 79% (27/34) | 88% (35/40) | ns |
| Β-blocker | 97% (33/34) | 88% (35/40) | ns |
| Spironolactone | 91% (31/34) | 95% (38/40) | ns |
| Digoxin | 24% (8/34) | 53% (21/40) | 0.017 |
| Diuretics | 82% (28/34) | 93% (37/40) | ns |
| Vasodilators | 34% (13/34) | 63% (25/40) | 0.037 |
| Patients with target doses of medication according guidelines (%) | 46% | 68% | <0.001 |
IQR, interquartile range; Specialized HF care considered (in-hospital or outpatient); HF, heart failure; HF-DMP, Disease Management Program for HF; Centers with at least one multidisciplinary member, centers having at least one of the following professions: cardiology, nursing, physiotherapy and/or physical educator or nutritionist; HF, heart failure; BNP, brain natriuretic peptide; DEIC, Heart Failure Department of the Brazilian Society of Cardiology; ESC, European Society of Cardiology; AHA, American Heart Association; MDP, multidisciplinary program; KCCQ, Kansas City Cardiomyopathy Questionnaire; MLHFQ, Minnesota Living with Heart Failure questionnaire; ACE-I Angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers.